Lenalidomid Stada (Lenalidomide)

Lenalidomide binds to the cereblon component of the CRL4‑CRBN E3 ubiquitin ligase complex, altering its activity. This leads to the degradation of specific transcription factors, resulting in anti‑angiogenic effects, modulation of the immune response, and direct anti‑tumor activity against malignant plasma cells and dysplastic marrow clones.

The prescribed dose of Lenalidomid Stada is individualized by the treating physician based on the patient’s diagnosis, disease stage, renal function, and prior therapies. Dosage adjustments and treatment cycles are determined by clinical guidelines and the prescriber’s judgment; patients should follow the exact regimen provided by their healthcare professional.

Lenalidomide is classified as teratogenic and may cause fetal harm; it is contraindicated in pregnancy. Both male and female patients of reproductive potential must use effective contraception during treatment and for a defined period after the last dose. Safety during breastfeeding has not been established, and nursing is generally discouraged.

To request Lenalidomid Stada, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with traditional chemotherapy, lenalidomide offers a targeted immunomodulatory approach with oral administration. It is often combined with dexamethasone or proteasome inhibitors, providing synergistic activity. While other agents such as bortezomib or carfilzomib are administered intravenously, lenalidomide’s oral route can improve convenience but requires careful monitoring of blood counts.

Lenalidomid Stada tablets should be stored at temperatures below 25 °C, in the original packaging to protect from moisture and light. Keep the product out of reach of children and do not use if the packaging is damaged or the tablets appear discoloured.

The medication is taken orally, usually once daily on a prescribed schedule that may include treatment days followed by rest periods. Tablets should be swallowed whole with water and not crushed or chewed unless directed by a healthcare professional. Adherence to the dosing calendar is essential for optimal efficacy.

The most critical safety concerns include severe cytopenias (especially neutropenia and thrombocytopenia), venous thromboembolism, and rare but serious skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored regularly for blood count changes and signs of clotting or severe skin events, and treatment should be adjusted or discontinued as clinically indicated.

Lenalidomid Stada is contraindicated in patients with known hypersensitivity to lenalidomide or any excipients, in pregnant women, and in individuals who cannot adhere to required contraception measures. Caution is also advised for patients with severe renal impairment or uncontrolled infections, and the drug should be avoided unless the prescriber determines that benefits outweigh the risks.